LLY Eli Lilly and Company

129.7
+1.4  (+1%)
Previous Close 128.3
Open 128.61
Price To Book 12.8
Market Cap 134345718074
Shares 1,035,818,952
Volume 2,974,794
Short Ratio 4.98
Av. Daily Volume 16,900,482

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met primary endpoint - February 4, 2019.
Baricitinib
Atopic dermatitis
Phase 1/2 updated data noted ORR of 59% - October 6, 2018.
LOXO-292
RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
FDA approval announced September 27, 2018.
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
Phase 3 trial to be initiated in 2018.
Baricitinib
Psoriatic arthritis
NDA filing announced November 14, 2018.
Lasmiditan - SPARTAN
Migraine
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 trial met primary endpoint - noted October 2, 2018.
Ultra rapid insulin
Diabetes
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Safety trial data due 2019.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 PFS data met primary endpoint but overall survival not improved. Will not seek regulatory approval.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 trial met primary endpoints - September 5, 2018.
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 initiated 1Q 2017.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 initiated 1Q 2017.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Approval announced February 26, 2018.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Approved October 4, 2017.
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
Phase 3 data released October 10, 2017 - primary endpoint not met.
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Approval announced December 1, 2017.
Taltz
Psoriatic Arthritis
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
FDA Approval announced November 26, 2018.
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.
Phase 3 trial met primary endpoint - noted June 25, 2018.
Empagliflozin
Type 1 Diabetes
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data released April 4, 2018. Primary endpoint met.
Ramucirumab REACH-2
Hepatocellular Carcinoma
Phase 3 PFS primary endpoint met - March 12, 2019.
Ramucirumab
Non-small cell lung cancer
Phase 3 trial met primary endpoint - noted June 28, 2018.
Ixekizumab
Axial Spondyloarthritis
Phase 3 trial met primary endpoint - July 19, 2018.
Tradjenta (linagliptin) - CARMELINA CV outcomes
Type 2 Diabetes
PDUFA date under priority review for sBLA announced March 5, 2019. No PDUFA date given - estimate July 2019.
Galcanezumab
Cluster headache
Phase 3 top-line data due 2021.
Mirikizumab (LY3074828)
Ulcerative Colitis
Phase 3 trial met composite endpoint - November 2018.
Trulicity REWIND CV outcomes
Type 2 diabetes
Phase 3 trial met primary endpoint of non-inferiority.
Tradjenta (linagliptin) - CAROLINA CV outcomes
Type 2 Diabetes
Phase 2 data due 2020.
N3pG Antipody
Alzheimer's disease
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met.
Tanezumab
Osteoarthritis
Phase 3 data due 2021.
Abemaciclib (Verzenio) - MonarchE
Breast cancer - adjuvant
Phase 2 data due 1H 2019.
Mirikizumab
Crohn's disease
Phase 3 data due 2020.
Mirikizumab
Psoriasis
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 top-line data due mid-2020.
AM0010 (PEG-IL-10) - Sequoia
Pancreatic ductal adenocarcinoma (PDAC)
Phase 2 top-line data due late 2019.
AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1
Non-small cell lung cancer (NSCLC)
Phase 2 top-line data due late 2019.
AM0010 (PEG-IL-10) and Nivolumab - Cypress 2
Non-small cell lung cancer (NSCLC)
Phase 1/2 initiation announced December 21, 2018.
LOXO-305
Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphomas (NHL)
Phase 3 data released January 18, 2018 did not meet primary endpoint. FDA had already awarded accelerated approval.
LARTRUVO (olaratumab)
Soft tissue sarcoma (STS)
Phase 3 data due 2019.
Taltz (Ixekizumab)
Non-radiographic axial spondyloarthritis
Phase 3 data due 2019.
Taltz (Ixekizumab)
Psoriasis

Latest News

  1. Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  2. PRESS DIGEST - Wall Street Journal - March 25
  3. Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know
  4. Bull of the Day: DexCom (DXCM)
  5. Better Buy: AbbVie vs. Eli Lilly
  6. Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
  7. Alkermes Focuses on Pipeline, Depends on Partners for Funds
  8. Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial
  9. 9 High-Margin Stocks Seen Leading in Fed's New Dovish Era
  10. Eli Lilly Stock Is Up Because UBS Sees Reasons to Be Bullish
  11. NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology
  12. Why Analysts Still Favor Eli Lilly and Company Stock
  13. See what the IHS Markit Score report has to say about Eli Lilly and Co.
  14. The Numbers Say Eli Lilly Stock Has Still More Upside For Investors
  15. Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
  16. The Case Against Pfizer Stock and the Rest of the Industry
  17. Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades
  18. Lilly's Cyramza Successful in Phase III First-Line NSCLC Study
  19. FDA medical adviser: 'Congress is owned by pharma'
  20. Lilly Announces Final Results of Elanco Exchange Offer